Pacific Biomarkers conducts studies primarily in Preclinical through Phase IV . Traditionally, PBI has conducted studies on the efficacy of drugs in a variety of therapeutic areas including cardiovascular, inflammation and bone. More recently, our company also has contributed its expertise to measuring drug safety in Acute Kidney Injury. The U.S. Food and Drug Administration and responsible pharmaceutical companies insist that testing for safety becomes an integral part of drug development.
By measuring biomarkers, we identify biological responses and monitor changes in physiology, pathology and pharmacology. PBI was founded in 1989. Our laboratory is one of only three U.S. members of the Cholesterol Reference Method Laboratory Network of the U.S. Centers for Disease Control. Pacific Biomarkers is compliant with Good Laboratory Practices (GLP), accredited with the American College of Pathologists (CAP), and certified according to the Clinical Laboratory Improvement Act (CLIA).